Journal
FRONTIERS IN MOLECULAR BIOSCIENCES
Volume 7, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmolb.2020.562798
Keywords
glioblastoma; molecular heterogeneity; transcription-based subtype; genetic alteration-based subtype; DNA methylation-based subtype; subtype-specific therapy
Categories
Funding
- Beijing Natural Science Foundation [Z190018]
- National Natural Science Foundation of China [81870123]
- China Postdoctoral Science Foundation [2018M641206]
- National Science Foundation for Young Scientists of China [81902545]
Ask authors/readers for more resources
Glioblastoma (GBM) is highly invasive and the deadliest brain tumor in adults. It is characterized by inter-tumor and intra-tumor heterogeneity, short patient survival, and lack of effective treatment. Prognosis and therapy selection is driven by molecular data from gene transcription, genetic alterations and DNA methylation. The four GBM molecular subtypes are proneural, neural, classical, and mesenchymal. More effective personalized therapy heavily depends on higher resolution molecular subtype signatures, combined with gene therapy, immunotherapy and organoid technology. In this review, we summarize the principal GBM molecular classifications that guide diagnosis, prognosis, and therapeutic recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available